Delving into the Latest Updates on ADD (Metabolic Pharmaceuticals) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

ADD-9903, ADD-9918, ADD-9922

+ [3]

Target-

Mechanism

Insulin sensitizers

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Polynovo Ltd.

Active Organization-

Inactive Organization

Polynovo Ltd.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Background: Patients with type 2 diabetes mellitus (T2DM) are at 2- to 4-fold higher risk of cardiovascular mortality compared with non-diabetic subjects. Cardiovascular disease (CVD) is the main cause of death in almost half of diabetic population in Spain. Female patients with T2DM have up to 40% excess risk of CVD compared with men and the causes are still unknown. It is argued that a tight control of cardiovascular risk factors could improve the situation.
Hypothesis: The cardiovascular risk factors management in women with T2DM is different than in men with T2DM.
Aims: To assess the therapeutic approach of cardiovascular risk factors and the occurrence of cardiovascular events among women in comparison to men with T2DM.
Methodology: Observational study based on clinical records of primary health care from T2DM patients in Catalonia (2007-2013).
Source: SIDIAP database. Analysis: The two study groups (women and men) will be matched to ensure balance in terms of basal comorbidities and previous cardiovascular disease in order to describe the study group characteristics and to perform a multivariate modeling approach.
Applicability and Relevance: This study is intended to serve to identify the points of improvement of the cardiovascular risk factors therapeutic approach in women.

Start Date01 Jan 2017

Sponsor / Collaborator-

100 Clinical Results associated with ADD (Metabolic Pharmaceuticals)

Login to view more data

100 Translational Medicine associated with ADD (Metabolic Pharmaceuticals)

Login to view more data

100 Patents (Medical) associated with ADD (Metabolic Pharmaceuticals)

Login to view more data

1,387

Literatures (Medical) associated with ADD (Metabolic Pharmaceuticals)

01 Dec 2024·Recent Patents on Nanotechnology

A Comprehensive Review on Prospects of Polymeric Nanoparticles for Treatment of Diabetes Mellitus: Receptors-Ligands, In vitro & In vivo Studies

Review

Author: Dawre, Shilpa ; Jain, Arinjay

Abstract:As per International Diabetes Federation Report 2022, worldwide diabetes mellitus (DM) caused 6.7M moralities and ~537M adults suffering from diabetes mellitus. It is a chronic condition due to β-cell destruction or insulin resistance that leads to insulin deficiency. This review discusses Type-1 DM and Type-2 DM pathophysiology in detail, with challenges in management and treatment. The toxicity issues of conventional drugs and insulin injections are complex to manage. Thus, there is a need for technological intervention. In recent years, nanotechnology has found a fruitful advancement of novel drug delivery systems that might potentially increase the efficacy of anti-diabetic drugs. Amongst nano-formulations, polymeric nanoparticles have been studied to enhance the bioavailability and efficacy of anti-diabetic drugs and insulin. In the present review, we summarized polymeric nanoparticles with different polymers utilized to deliver anti-diabetic drugs with in vitro and in vivo studies. Furthermore, this review also includes the role of receptors and ligands in diabetes mellitus and the utilization of receptor-ligand interaction to develop targeted nanoparticles. Additionally, we discussed the utility of nanoparticles for the delivery of phytoconstituents which aids in protecting the oxidative stress generated during diabetes mellitus. Atlast, this article also comprises of numerous patents that have been filed or granted for the delivery of antidiabetic and anticancer molecules for the treatment of diabetes mellitus and pancreatic cancer.

01 Nov 2024·Parkinsonism & Related Disorders

Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study

Article

Author: Bitan, Michal ; Rozani, Violetta ; Bezimianski, Miri Glikshtein ; Azuri, Joseph ; Peretz, Chava

BACKGROUNDEmerging evidence suggests a potential association between certain anti-diabetic drugs and a reduced risk of Parkinson's disease (PD). Limited population-based studies have investigated users of newer anti-diabetic drugs such as GLP-1 agonists or SGLT2 inhibitors.OBJECTIVEThe aim of this study was to assess the risk of PD among individuals with type 2 diabetes mellitus (T2DM) who were treated with various types of anti-diabetic drugs over time.METHODSA population-based cohort comprising T2DM patients aged over 30 who used metformin, GLP-1 agonists, thiazolidinediones, sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors, or meglitinides between January 1, 1999 and December 31, 2018. Data were obtained between the diabetes registration and drug purchase databases of Maccabi Healthcare Services. Time-dependent Cox regression models, adjusted for sex, age, and comorbidities were employed to calculate the adjusted hazard ratios (HRs) for the PD risk associated with different anti-diabetic drugs over time.RESULTSThe study population comprised 86,229 T2DM patients, with 53.9 % males. The mean age at the first anti-diabetic drug purchase was 59.0 ± 11.0 and 62.0 ± 11.0 years for men and women respectively. Compared to metformin, several drug types were associated with a significantly lower PD risk: thiazolidinediones (HR = 0.91, 95 % CI:0.074-1.14); DPP4 inhibitors (HR = 0.60, 95 % CI:0.53-0.67); meglitinides (HR = 0.63, 95 % CI:0.53-0.74); GLP-1 agonists (HR = 0.54, 95 % CI:0.39-0.73); and SGLT2 inhibitors (HR = 0.15, 95 % CI:0.10-0.21).CONCLUSIONSOur results suggest a reduced risk of PD with certain anti-diabetic drugs, particularly SGLT2 inhibitors and GLP-1 agonists. Validation through extensive big-data studies is essential to confirm these results and to optimize PD prevention and management.

01 Nov 2024·Pharmacological Research

An in-depth look at the relationship between anti-diabetic drugs and Alzheimer’s disease

Letter

Author: Liu, Hangyu ; Huang, Shiyi

100 Deals associated with ADD (Metabolic Pharmaceuticals)

Login to view more data